Humoral hypercalcemia of malignancy is a common paraneoplastic syndrome which is responsible for significant patient morbidity and mortality. Parathyroid hormone- related protein (PTHrP) appears to be a major hormonal mediator of HHM due to the similar biologic actions that it shares with PTH. However, despite these similar biologic actions, HHM and primary hyper- parathyroidism (HPT) have different clinical characteristics. Reasons for this are likely complex and may be partly due to other tumor- associated factors or different actions of various PTHrP fragments. The long term objectives of this proposal are to develop animal models that will define 1) the role of PTHrP and other tumor- associated factors in the pathophysiology of HHM, 2) whether other tumor- associated factors can modulate the end organ effects of PTHrP and explain differences between HHM and HPT, 3) the role of various PTHrP fragments in vivo, and 4) whether different actions of PTHrP fragments contribute to the differences between HHM and HPT. The specific research proposed is intended to accomplish the development of a system of animal models of HHM that will permit comparison of individual factors to multiple known factors in a controlled setting with standard parameters of calcium homeostasis. These models will also enable similar study of the effects of continuous tumor secretion of PTHrP alone, either intact-(1-141) or carboxyl-truncated-(1-84) or -(1-106). The research design is constructed according to the long term specific objectives. Specifically, tumor models utilizing Chinese hamster ovarian (CHO) cells transfected with the cDNA for human PTHrP-(1-141) will be characterized and compared with CHO models which secrete other hypercalcemic factors (TNF, TGF alpha and IL-6) in nude mice in a controlled setting using standard parameters of calcium homeostasis. Each respective CHO tumor will be mixed with CHO tumors expressing PTHrP-(1-141) and compared with results of each individual factor as well as with a CHO tumor that secretes human PTH-(1- 84) and a human tumor (RWGT2) that causes HHM (mediated through PTHrP). CHO tumors that secrete carboxyl-truncated PTHrP-1(84) and -(1-106) will be constructed and compared with PTHrP- (1-141) in nude mice. Parameters of calcium homeostasis to be measured in all experimental groups are whole blood ionized calcium, urinary calcium, serum phosphorus, serum 1,25 dihydroxy vitamin D as well as bone histology and histomorphometry. The role of PTHrP, PTHrP fragments and other tumor-associated factors in HHM as well as their respective contributions to the differences between HHM and HPT should be made clear through the use of these models.Ultimately, they should contribute to the development and testing of therapy for HHM.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08AR001899-01
Application #
3079373
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1993-04-01
Project End
1998-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Guise, T A; Yin, J J; Thomas, R J et al. (2002) Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30:670-6
Guise, T A (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-8
Thomas, R J; Guise, T A; Yin, J J et al. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-8
Lemieux, P; Harvey, J; Guise, T et al. (1999) Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo. J Bone Miner Res 14:1570-5
Yin, J J; Selander, K; Chirgwin, J M et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206
Guise, T A; Mundy, G R (1998) Cancer and bone. Endocr Rev 19:18-54
Uy, H L; Mundy, G R; Boyce, B F et al. (1997) Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 57:3194-9
Guise, T A (1997) Parathyroid hormone-related protein and bone metastases. Cancer 80:1572-80
Guise, T A; Mundy, G R (1996) Physiological and pathological roles of parathyroid hormone-related peptide. Curr Opin Nephrol Hypertens 5:307-15
Guise, T A; Yin, J J; Taylor, S D et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-9

Showing the most recent 10 out of 12 publications